Literature DB >> 11238088

CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease.

C Buri1, M Körner, P Schärli, D Cefai, M Uguccioni, C Mueller, J A Laissue, L Mazzucchelli.   

Abstract

Lymph nodes with Hodgkin disease (HD) harbor few neoplastic cells in a marked leukocytic infiltrate. Since chemokines are likely to be involved in the recruitment of these leukocytes, the expression of potentially relevant chemokines and chemokine receptors were studied in lymph nodes from 24 patients with HD and in 5 control lymph nodes. The expression of regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta was analyzed by in situ hybridization and that of CCR3 and CCR5 by immunohistochemistry and flow cytometry. It was found that, overall, the expression of all 4 chemokines was markedly enhanced, but the cellular source was different. RANTES was expressed almost exclusively by T cells whereas the expression of MCP-1, MIP-1alpha, and MIP-1beta was confined largely to macrophages. In control lymph nodes, chemokine expression was low, with the exception of MIP-1alpha in macrophages. CCR3 and CCR5 were highly expressed in T cells of HD involved but not of control lymph nodes. CCR3 was equally distributed in CD4+ and CD8+ cells, but CCR5 was associated largely with CD4+ cells. In HD lymph nodes, CCR3 and CCR5 were also expressed in B cells, which normally do not express these receptors. All these chemokines and receptors studied, by contrast, were absent in the neoplastic cells. It was concluded that chemokines are involved in the formation of the HD nonneoplastic leukocytic infiltrate. Expression of CCR3 and CCR5 appears to be characteristic of HD, but the roles of these receptors' up-regulation for the disease process remain unclear.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238088     DOI: 10.1182/blood.v97.6.1543

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.

Authors:  Paul G Rubinstein; David M Aboulafia; Andrew Zloza
Journal:  AIDS       Date:  2014-02-20       Impact factor: 4.177

2.  Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells.

Authors:  Paul Greaves; Andrew Clear; Andrew Owen; Sameena Iqbal; Abigail Lee; Janet Matthews; Andrew Wilson; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2013-09-04       Impact factor: 22.113

3.  Primary central nervous system lymphoma secretes monocyte chemoattractant protein 1.

Authors:  Ryuhei Kitai; Kazuyo Ishisaka; Kazufumi Sato; Takahiro Sakuma; Takahiro Yamauchi; Yoshiaki Imamura; Hideki Matsumoto; Toshihiko Kubota
Journal:  Med Mol Morphol       Date:  2007-03-29       Impact factor: 2.309

4.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

5.  Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue.

Authors:  Alex Reza Gholiha; Peter Hollander; Liza Löf; Anders Larsson; Jamileh Hashemi; Johan Mattsson Ulfstedt; Daniel Molin; Rose-Marie Amini; Eva Freyhult; Masood Kamali-Moghaddam; Gunilla Enblad
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

6.  Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.

Authors:  J Panse; K Friedrichs; A Marx; Y Hildebrandt; T Luetkens; K Barrels; C Horn; T Stahl; Y Cao; K Milde-Langosch; A Niendorf; N Kröger; S Wenzel; R Leuwer; C Bokemeyer; S Hegewisch-Becker; D Atanackovic
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

Review 7.  Microenvironment Cell Contribution to Lymphoma Immunity.

Authors:  Deepika Kumar; Mina L Xu
Journal:  Front Oncol       Date:  2018-07-27       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.